Introduction
Macrophage inhibitory cytokine-1 (MIC-1) (also known as PDF, GDF-15, PLAB, PTGFB, and NAG-1), is a divergent member of the TGF-b superfamily that was first isolated from a substracted cDNA library enriched for genes associated with macrophage activation (Bootcov et al., 1997) . The MIC-1 gene is highly expressed in placenta and in adult prostate tissue, and at lower levels in liver, kidney, pancreas, and fetal brain (Fairlie et al., 1999; Hromas et al., 1997; Lawton et al., 1997; Paralkar et al., 1998) . In the brain, MIC-1 is expressed in epithelial cells of the choroid plexus and secreted into the cerebral spinal fluid (Strelau et al., 2000) . Members of the TGF-b superfamily are synthesized as precursor proteins, which are cleaved at a dibasic or furin-like RXXR site to release the C-terminal mature protein. The active mature MIC-1 protein is secreted as a 30 kDa dimeric peptide after proteolytic cleavage at the furin-like site RRAR of the inactive 80 kDa propeptide dimer. During secretion through ER and Golgi, the pro-MIC-1 protein is N-glycosylated at amino acid 70 (Bauskin et al., 2000) . Members of the TGF-b superfamily are multifunctional hormones, and the nature of their effects depends on the cellular context. They regulate a broad range of cellular functions including proliferation, inflammation, apoptosis, angiogenesis, adhesion, terminal differentiation, and developmental fate (Whitman, 1998) .
It has been reported that MIC-1, like TGF-b, requires an intact signaling pathway mediated by type I (TbR-I) and type II (TbR-II) TGF-b receptors, as well as receptor activated Smad4 (Tan et al., 2000) . It has been shown that MIC-1 exerts divers biological functions in distinct cellular contexts. It inhibits the late phase of macrophage activation (Bootcov et al., 1997) and inhibits proliferation of immature hematopoietic progenitors (Hromas et al., 1997) , breast carcinoma cell lines (Li et al., 2000) , mink lung epithelial cells, and prostate carcinoma cells (Tan et al., 2000) . Moreover, MIC-1 has been shown to be involved in embryonic, osteogenic (Paralkar et al., 1998) , and hematopoietic development (Detmer et al., 1999) . Strelau et al. (2000) reported an important function of MIC-1 in the central nervous system as both a neurotrophic and a neuroprotective factor for midbrain dopaminergic neurons in vitro and in vivo.
Glioblastoma is the most frequent human primary brain tumor and represents the ultimate and most malignant stage of astrocytoma progression. Inactivation of the tumor suppressor gene p53 represents one of the earliest genetic alterations known in progression of astrocytomas. Activation of p53 in response to various forms of cellular stress leads to transactivation of p53 target genes such p21, GADD45, and bax, involved in tumor suppressing functions including cell cycle arrest, DNA repair, and apoptosis (Levine, 1997) . Furthermore, wild-type p53 function comprises suppression of complex processes including angiogenesis and metastasis for which the molecular mechanisms mediating p53 signaling have not yet been elucidated (Van Meir et al., 1994) . Knowledge of biological functions of such downstream genes are central to a better understanding of the consequences associated with p53 function in tumor development, and may lead to the discovery of novel molecular targets for cancer therapy.
In order to identify new p53 target genes relevant to glioblastoma development, we re-established p53 expression in the p53-null glioblastoma cell line LN-Z308 (Albertoni et al., 1998) using the Tet-On inducible system (Gossen et al., 1995; Kessler et al., 2000) . Subsequent gene expression profiling led to the identification of MIC-1 as a novel p53 target. We demonstrate that MIC-1 mRNA expression is upregulated by anoxia, and that this effect occurs independently of p53 and HIF-1 (hypoxia inducible factor 1). Overexpression of MIC-1 in glioblastoma cell lines abolishes their capacity to form tumors in nude mice. Since the cells themselves proved to be insensitive to MIC-1 mediated growth arrest in vitro, MIC-1 may act in a paracrine fashion in vivo. The regulation of MIC-1 expression in response to various kinds of cellular stress mediated by distinct pathways suggests a potential role of MIC-1 in protection against cellular damage and tumor progression.
Results

Up-regulation of MIC-1 expression by p53
In order to identify novel p53-target genes implicated in the development of glioblastoma, we re-established p53 expression in the p53-null glioblastoma cell line LN-Z308 using the Tet-On system developed by Gossen and Bujard (1992) . The LN-Z308 derived clone 2024 exhibits doxycycline dependent p53 induction (Kessler et al., 2000) and was employed to identify new p53 target genes using cDNA-macroarray. Gene expression profiles, revealing p53 dependent gene expression patterns of 2024 cells (not shown), identified MIC-1 as a p53 target gene in line with previous reports (Kannan et al., 2000; Li et al., 2000; Tan et al., 2000) . Its expression increased 8.7-fold following p53 induction. This level of induction was the highest obtained in this experiment and was even higher than the observed induction of p21 (7.4-fold). MIC-1 upregulation by p53 was confirmed by Northern blot analysis in 2024 cells, as well as in a second LN-Z308 derived Tet-On p53 cell line, C1612, and in a dexamethasone-dependent p53-inducible glioblastoma cell line, GM 47-23, demonstrating that p53-dependent MIC-1 up-regulation is not restricted to clone 2024 ( Figure 1a) . Up-regulation of the MIC-1 gene upon p53-induction correlated with an increase of secreted MIC-1 protein in the culture media of 2024 and C1612 cells conditioned for 24 h. Western blot analysis revealed two bands of 44 kDa and 15 kDa, corresponding to pro-MIC-1 and mature MIC-1 protein, respectively (Figure 1b) . The size of the pro-MIC-1 protein is 4 kDa bigger than the predicted size of 40 kDa which is consistent with N-glycosylation (Bauskin et al., 2000) . While our studies on p53-dependent MIC-1 gene regulation were being completed, three groups (Kannan et al., 2000; Tan et al., 2000) published similar results using different cell lines. Two p53 responsive elements in the promoter region have been described (Li et al., 2000; Tan et al., 2000) .
p53-independent up-regulation of MIC-1 in anoxia Anoxia is an important physiological stress associated with rapid tumor growth and in some tumor types is reflected in the development of tumor necrosis, which represents a histological hallmark of glioblastoma multiforme. MIC-1 mRNA levels where induced within 24 h of anoxia as monitored by Northern blot analysis in the three glioblastoma cell lines LN-Z308, LN-229, and U87 (Figure 2 ). This up-regulation was also observed upon CoCl 2 treatment that mimics stress related to low oxygen tension (Chandel et al., 1998) . Since LN-Z308 cells are p53-null, LN-229 cells carry mutant p53, and U87 cells harbor a wt-p53 gene, we conclude that MIC-1 expression is up-regulated by anoxia: independent of the p53 status.
HIF-1 independent up-regulation of MIC-1
Hypoxia inducible factor 1 (HIF-1), a key element in response to anoxia, has been described to induce erythropoiesis, angiogenesis, and glycolysis. HIF-1 is a heterodimeric transcription factor, consisting of a and b subunits. HIF-1b is constitutively expressed, while HIF-1a expression is up-regulated by low cellular oxygen tension. Dimerization of HIF-1a with HIF-1b forms the active HIF-1, which enters the nucleus and induces transcription of specific genes, such as p21, erythropoietin, VEGF, and phosphoglycerokinase (PGK-1) (Carmeliet et al., 1998) . In order to test whether HIF-1 is involved in MIC-1 up-regulation during anoxia, we used two mouse hepatoma cell lines, Hepa1C1C7 and HepaC4. HepaC4 cells are variants of Hepa1C1C7 cells that lack active HIF-1 due to a single point mutation, G326D, in the HIF-1b subunit which reduces specific binding to DNA target sequences (Numayama-Tsuruta et al., 1997; Salceda et al., 1996) . Thus, VEGF, a well characterized HIF-1 target gene, is up-regulated by anoxia in Hepa1C1C7 cells (wild-type HIF-1b), but not in HepaC4 cells (mutant HIF-1b). In contrast, MIC-1 gene expression was increased by anoxia independently of the status of HIF-1 (Figure 3 ). These results demonstate that MIC-1 expression is up-regulated in response to oxygen deprivation in a HIF-1-independent manner.
MIC-1 protein expression and secretion in anoxia
We further investigated whether the up-regulation of MIC-1 mRNA correlates with an increase of MIC-1 protein secretion of anoxic cells. The amount of MIC-1 protein secreted by glioblastoma cells in anoxia was comparable to cells grown under normoxic conditions ( Figure 4a ). In contrast, an intracellular accumulation of pro-MIC-1 protein was observed in cell extracts after anoxic treatment (Figure 4b ). These results suggest that upon anoxic stress induction of MIC-1 mRNA correlates with the increase of total pro-MIC-1 protein synthesis, but not with increased secretion of the active form of MIC-1 protein. In contrast to MIC-1, VEGF protein secretion increases during anoxia. Furthermore, in LN-Z308 derived clones 2024 and C1612, the secretion of MIC-1 protein is enhanced following induction of p53 under normoxic conditions ( Figure  1b) suggesting that the MIC-1 protein is correctly processed and secreted in normoxia. Taken together, Figure 2 Induction of MIC-1 mRNA in glioblastoma cell lines under anoxic conditions. Northern blot analysis of MIC-1 in cell lines LN-Z308 (p53 null), LN-229 (p53 mutant), and U87 (p53 wild-type) after exposure to anoxia (A), or treatment with different concentrations of cobalt chloride (C 100 , 100 mM; C 200 , 200 mM; and C 400 , 400 mM), respectively. N, normoxia; t o , time 0 the intracellular accumulation of pro-MIC-1 protein and the lack of increased MIC-1 protein secretion during anoxia do not appear to be due to a general defect in the secretory machinery of LN-Z308 and LN-229 cells, but might be related to oxygen deprivation. We further investigated the effect of reoxygenation on MIC-1 mRNA expression and protein secretion. LN-Z308 cells were pre-incubated under anoxic conditions during 24 h, washed in PBS and then incubated in fresh serum free media under normoxic conditions (reoxygenation). Control cells received the same treatment, but were pre-incubated under normoxic conditions. The level of MIC-1 mRNA increased during anoxia and progressively decreased following reoxygenation, attaining basal levels after 12 h of recovery ( Figure 5a ). The kinetics of this process was comparable to down-regulation of VEGF mRNA expression during reoxygenation. In contrast, at the protein level, the re-establishment of normal oxygen levels led to a rapid increase of MIC-1 protein in the culture media with a plateau reached at 3 h, suggesting release of accumulated MIC-1 protein from the cells within 3 h (Figure 5b ).
Anti-tumorigenic activity of MIC-1 in nude mice
In order to investigate the relevance of MIC-1 expression in tumor development, we examined whether MIC-1 overexpression affects tumor growth in vivo. To this end, we transfected the tumorigenic LN-Z308 cell line with a human MIC-1 expression vector pcDNA-3neo-MIC-1 or with the empty vector pcDNA-3neo. Western blot analysis confirmed overexpression of MIC-1 secretion in three selected MIC-1 transfected clones (3M1, 3M2 and 3M11), while the pool of three pcDNA-3neo clones (control pool) expressed levels comparable to the parental cell line (Figure 6a ). The proliferation rate of 3M1, 3M2 and 3M11 cells, in vitro, was not affected by MIC-1 overexpression and was comparable to the proliferation rate of the parental cell line and control pool ( Figure  6b ). We then analysed whether MIC-1 overexpression could affect the tumorigenic capacity of these cells in vivo. The MIC-1 overexpressing clones (3M1, 3M2 or 3M11) and the control pool were injected subcutaneously into the flanks of five Swiss nude mice, respectively. Tumor growth was observed and measured over a time period of 4 months (Figure 6c ). The capacity to form tumors was completely lost by MIC-1 overexpressing cells, while the cells of the control pool retained tumorigenic properties. These results were confirmed in a second independent experiment. Since the proliferation rate of MIC-1 overexpressing cells in vitro was similar to the proliferation rate of the control cells, inhibition of tumorigenicity by MIC-1 observed in vivo might involve in part a paracrine effect of MIC-1 on the host cells. 
Discussion
Our present work has shown that anoxia, one of the most important physiological stresses, induces MIC-1 gene expression in glioblastoma cell lines. Using an inducible system for wild-type p53, we and others have identified MIC-1, a TGF-b family member, as a p53 target gene (Kannan et al., 2000; Li et al., 2000; Tan et al., 2000) . p53 -dependent up-regulation of MIC-1 is comparable or even stronger than induction of p21, suggesting a significant role for MIC-1 as p53 induced mediator. Although it has been reported that p53 protein is stabilized in response to oxygen deprivation Chandel et al., 2000) , this is not essential for anoxia stimulated up-regulation of MIC-1 mRNA, as demonstrated in p53-null glioblastoma cell line LN-Z308 (Figure 2) . Furthermore, MIC-1 upregulation in anoxia also occurs in a HIF-1 independent manner. HIF-1 is known as one of the most important transcription factors involved in oxygen homeostasis (Carmeliet et al., 1998) . The analysis of the MIC-1 gene promoter revealed the presence of putative consensus sequences for several transcription factors, including AP-1 and, Sp1 and Sp3 (Baek et al., 2001a; Bottner et al., 1999; Lawton et al., 1997) . AP-1 has been shown previously to act as an anoxic stress mediator in glioblastoma cell lines LN-229 and LN-Z308 (Desbaillets et al., 1999) and might be a possible candidate in anoxia mediated MIC-1 up-regulation. However, it remains to be seen whether modulation of MIC-1 represents a specific response to anoxia or rather a secondary effect of anoxia, such as ATP depletion and cell injury. At the protein level, we have shown that anoxia leads to intracellular pro-MIC-1 accumulation, while following reoxygenation the MIC-1 protein is processed and secreted. This observation points out a link between cellular oxygen tension and MIC-1 protein processing. However, the biological significance of this observation is unclear. Following re-establishment of normoxic conditions, processing of accumulated pro-MIC-1 and subsequent release of the mature protein might counteract proangiogenic stimuli, or act as a survival factor, as was demonstrated recently for lesioned dopaminergic neurons (Strelau et al., 2000) . To our knowledge, this kind of regulation has never been reported before.
The fact that several important stress signaling pathways, p53-dependent and independent, up-regulate MIC-1 expression infers a central role for MIC-1 in response to cellular stress. Induction of MIC-1 expression has been reported from hepatocytes situated in necrotic areas caused by experimentally induced liver injury (Hsiao et al., 2000) , in neurons following cryolesions (Schober et al., 2001) , and p53 independent upregulation of MIC-1 has been shown as result of DNA damage, brought by genotoxic agents or irradiation (Li et al., 2000) , but also upon treatment with nonsteroidal anti-inflammatory drugs such as Sulindac (Baek et al., 2001b) . There are several reports describing MIC-1 as a mediator of p53-dependent or , and 3M11, respectively, into athymic nude mice failed to yield tumors. In contrast, the pool of vector transfectants retained inherent tumorigenic properties. This data is representative of two independent experiments. The initial measurement corresponds to the volume of the injected cells p53-independent growth arrest and apoptosis (Baek et al., 2001a; Li et al., 2000; Tan et al., 2000) . However, in our experiments, proliferation of glioblastoma cell lines is neither affected by incubation with increasing concentrations of MIC-1 enriched conditioned media (not shown), nor by ectopic expression of MIC-1 (Figure 6 ). Similarly, it has been reported that TGF-b, a potent growth inhibitor on many cell types, did not affect proliferation of glioblastoma cell lines (Yamada et al., 1995) . Like TGF-b, MIC-1 growth suppression requires an intact TGF-b/Smad4 signaling pathway mediated by TGF-b type I (TbR-I) and type II (TbR-II) receptors, as well as receptor activated Smad4 (Tan et al., 2000) . Thus, the lack of the inhibitory effect of MIC-1 on LN-Z308 cell proliferation might be due to a defect in the TGF-b/Smad signaling pathway. In contrast, the capacity of glioblastoma cell line LN-Z308 to form tumors in nude mice was completely abolished upon ectopic expression of MIC-1 cDNA, while retained in the assay with the vector control. Because the proliferation rate of MIC-1 over-expressing cells in vitro was similar to the proliferation rate of the control cells, the inhibition of tumorigenicity observed in vivo is most likely an effect mediated by the microenvironment, suggesting a paracrine activity of MIC-1 protein on the host cells interacting with the tumor.
During the preparation of this article, Baek and coworkers published evidence of an anti-tumorigenic function of MIC-1 ectopically expressed in the colon carcinoma cell line HCT-116 (Baek et al., 2001b) . They reported an increased basal apoptosis in vitro, reduced soft agar cloning efficiency, and reduction of tumorigenicity in nude mice. These observations, together with our results, suggest that the anti-tumorigenic function of MIC-1 is not cell type specific. However, MIC-1 might affect tumor formation through both autocrine regulation of tumor cell growth in MIC-1 sensitive cells (e.g. HCT-116 cells) and in addition through a paracrine mechanism acting on the host cells, as suggested here with cells non-responsive to MIC-1.
Whether MIC-1 regulates expression of factors involved in anti-tumorigenic processes, such as inhibition of angiogenesis, is not known. Smad4, a key factor in the TGF-b/MIC-1 signaling pathway has been shown to exert an important anti-angiogenic function (Schwarte-Waldhoff et al., 2000) . Thus, it is possible that MIC-1, like TGF-b displays an indirect effect on regulation of angiogenesis mediated by the Smad4 pathway. A dose dependent effect of TGF-b on VEGFinduced angiogenesis has previously been described in vitro. At high concentrations TGF-b inhibits angiogenesis (Pepper et al., 1993) by decreasing expression of the VEGF receptor-2 (FLK-1) in vascular endothelial cells (Mandriota et al., 1996) .
In conclusion, the p53 target gene MIC-1 is upregulated in response to anoxia, independently of p53 and HIF-1. Ectopic expression of MIC-1 in glioblastoma cell line LN-Z308, that are insensitive to MIC-1 mediated growth suppression in vitro, completely abolished tumorigenicity in vivo. These experiments allowed separation of the autocrine anti-tumorigenic effect of MIC-1 providing evidence for paracrine antitumorigenic properties of MIC-1 mediated by the host micro environment in vivo. It remains to be demonstrated whether these anti-tumorigenic properties are based on an anti-angiogenic effect as might be suggested due to the regulatory effect of anoxia on MIC-1 and the link to Smad4 in the MIC-1 signaling pathway.
Materials and methods
Cell culture, plasmids, gene transfer, and cell proliferation assay
The human glioblastoma cell lines LN-229, LN-Z308, and T98G and their respective culture conditions have been described before (Ishii et al., 1999) . The murine hepatoma cell lines Hepa1C1C7 and HepaC4 were kindly provided by Dr M Gassmann (Numayama-Tsuruta et al., 1997; Salceda et al., 1996) .
The cell lines were subjected to anoxia using an Oxoid Gas generating anaerobic chamber (Unipath Ltd, Hampshire, UK) as described (Desbaillets et al., 1999) . Cobalt chloride treatment was performed by incubating cells with cobalt chloride at different concentrations (100, 200 or 400 mM) for 24 h (Tenan et al., 2000) . In these experiments, cells were cultured in serum free medium during treatment. In all experiments with a time course, at time 0 (t=0) cells were washed and fresh serum free medium was added.
Transfections of glioblastoma cell lines were performed using either calcium phosphate suspension technique or DOTAP (Boehringer), according to manufacturer's instructions.
p53-inducible cell lines were obtained by re-establishment of wild-type p53 expression in LN-Z308 using the Tet-On System (Gossen et al., 1995) . LN-Z308 cells were cotransfected with the reverse tetracycline transactivator (rtTA), plasmid pUHG 17.1 (Gossen et al., 1995) and plasmid pJ6O, containing the puromycin resistance gene (Morgenstern and Land, 1990) . Selected clones (puromycin 1 mg/ml) were tested for doxycycline-regulated rtTA transactivation by transient transfection of the luciferase reporter gene under the control of a minimal promoter containing tetO-binding sites (pUHC13.6, kindly provided by Dr Bujard). Clone C16, exhibiting optimal doxycycline-regulated rtTA transactivation was retained to introduce wild-type p53 under the control of a minimal promoter (PhCMV) containing seven tetO-binding sites. The p53-inducible clone 2024 was obtained by cotransfection of C16 cells with pUHG-p53wt (Van Meir et al., 1994) and pcDNA3-neo for neomycin selection (Invitrogen). Similarily, the p53 -inducible clone C1612 was obtained after transfection of cell clone C16 with pHS-53, derived from pUHG10.3 (Gossen and Bujard, 1992) . The plasmid pHS-53 comprises the 1.8 Kb BamHI fragment of wild-type p53 cDNA (pUHG-p53WT) in the BamHI site and the hygromycin resistance gene (taken from plasmid pLSHL, kindly provided by Dr T Friedmann) introduced into the XhoI site. Clones 2024 and C1612 were selected with either 600 mg/ml G418 or 250 mg/ml Hygromycin B, respectively. Expression of wild-type p53 was induced with 2 mg/ml doxycycline. The T98G derived, p53-inducible cell line GM47-23 was kindly provided by Dr Mercer and cultured as described (Mercer et al., 1990) . Wild-type p53 expression was induced by 1 nM dexamethasone.
Glioblastoma cells stably expressing MIC-1 were obtained by transfecting the pcDNA3-neo-MIC-1 into LN-Z308 cells. The plasmid was constructed by inserting the HindIII/XbaI restriction fragment comprising the 1.4 Kb MIC-1 cDNA derived from plasmid PDF-pCR3.1-uni (Paralkar et al., 1998) into the pcDNA3-neo expression vector (Invitrogen). As control, cells were transfected with pcDNA3-neo control vector only. Clones were selected with G418 (800 mg/ml) for 2 weeks. Supernatants of selected clones, conditioned for 48 h, were collected and analysed for MIC-1 secretion by Western blot. Clones 3M1, 3M2, and 3M11 were retained as MIC-1 secreting clones, while a pool of three selected pcDNA3-neo clones was retained as negative control.
For the proliferation assay, cells were seeded in 24 well plates (10 000 cells/well) and allowed to adhere for 24 h. At time 0 (t=0) cells were washed and fresh medium was added. Cell number was determined by a colorimetric assay after crystal violet staining, basically as described (Bonnekoh et al., 1989) . The growth curve was normalized by the measurement at t=0. Each time point was performed in triplicate.
RNA extraction and Northern blot analysis
Total RNA was isolated using the Trizol TM method (Gibco BRL). Northern blot analysis was performed as described previously using 10 mg of total RNA (Desbaillets et al., 1997; Tenan et al., 2000) .
Probes were radioactively labeled employing the random primed DNA labeling kit (Boehringer) using [a- 32 P]dCTP (3000 Ci/mmol, Amersham). The Northern blots were hybridized with the plasmid derived probes for p21 (NotI/ EcoRI-fragment of pCEP-WAF1-S (el-Deiry et al., 1994)) and VEGF165 (Vascular Endothelial Growth Factor; EcoRI/BamHI-fragment of pBspt-KS-VEGF165 (Plate et al., 1992) ), and PCR-derived probes for p53 exon 5 -8 (cctgccctcaacaagatgtt, ggtgaggctcccctttcttg, 508 bp), human MIC-1 (cgaggtgcaagtgaccatgtg, tggctaacaagtcatcataggtct, 212 bp), and murine MIC-1 (gcacaccctaaggacatgagt, ccttgaaggggagtgtaggtg, 719 bp).
Expression profiling of p53 inducible genes
The Atlas TM Human Cancer 1.2 Array (Clontech Laboratories, Inc.) featuring unique sequences for 1176 genes was used to determine expression profiles using the reagents provided and following the instructions of the manufacturer (#PT3140-1; version #PR9X390) with minor modifications. In brief, total RNA from 2024 cells 'p53-off' or 2024 cells treated for 24 h with 2 mg/ml doxycycline 'p53-on' was isolated. Two mg total RNA were radiolabeled, by reversetranscription with Superscript II (Stratagene) at 488C in the presence of [a- 32 P]dATP (10 mCi/ml; 3000 Ci/mmol, Amersham #PB10204). Radiolabeled first strand cDNA was purified with Qiaquick Nucleotide Removal Kit (Qiagen). Probes were hybridized over night at 688C to Atlas TM Human Cancer 1.2 Arrays. The membranes were washed under high stringency conditions. Data acquisition was performed on a phosphorimager (Fuji BAS 1000) followed by data analysis using ATLASImage 1.5 software (Clontech Laboratories, Inc.).
Immunoblot analysis
Total cellular proteins were extracted after incubation of the cells for 20 min on ice in lysis buffer (1% Triton X-100, 0.15 mM NaCl, 0.05 mM Tris-HCl, 0.02% NaN 3 , 5 mM EGTA, 5 mM EDTA, 1 mM PMSF, 1 mM Aprotinin, 1 mM Leupeptin and 1 mM Pepstatin). The lysate was centrifuged (14 000 r.p.m., 48C, 15 min), and the supernatant was stored at 7208C for further use. Secreted proteins were isolated from serum free media conditioned during 24 to 72 h, precipitated in 7.2% TCA, 1.5% DOC, washed in acetone, resuspended in 1% SDS, 0.1 N NaOH, and stored at 7208C. Protein concentrations were determined using 'BCA protein assay' (PIERCE) according to manufacturer's instructions. Proteins (100 mg of intracellular proteins, or 10 mg of secreted proteins) were separated either on reducing SDS-polyacrylamide gels, or under non-reducing conditions for VEGF analysis, and transferred onto PVDF membranes (Millipore). Equal protein loading was confirmed by Ponceau red staining. MIC-1 and VEGF were detected using sheep polyclonal antiserum 233 anti-human MIC-1 (Bootcov et al., 1997; Fairlie et al., 2001) or mouse anti-human VEGF (clone 26503.11, dilution 1 : 125; R&D Systems), respectively. The corresponding secondary antibodies used were PODconjugated Rabbit Anti-sheep IgG (DAKO) and Horseradish POD-conjugated Anti-mouse IgG (Sigma-Aldrich). The blots were developed with the BM Chemoluminescence Blotting Substrate POD Kit (Boehringer) and exposed to X-ray films (Kodak X-OMAT AR or MR, Eastman, Kodak, Rochester, NY, USA).
Nude mouse tumorigenicity assay 10 7 cells were resuspended in DMEM media and subcutaneously injected into the flanks of 6 -9 week-old female Swiss nu/nu mice (IFFA Credo, France). Five mice per group were injected, and two independent experiments were performed. Tumor sizes were measured weekly with a caliper. Tumor volume (mm 3 ) was calculated as (length6width 2 )/2.
